MetaCap

Talphera Inc. (TLPH)

NASDAQ: TLPHHealth CareBiotechnology: Pharmaceutical PreparationsUSD

0.7852+0.0462 (+6.25%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

TLPH stock chart

Technical analysis

Key statistics

All statistics
Market cap
$40.80M
EPS (TTM)
-$0.21
52-week range
0.69 – 1.57
Day range
0.7181 – 0.84
Volume / Avg
325.22K / 144.13K
Beta
—

52-week range

$0.69$1.57

TLPH stock today

Shares of Talphera (TLPH) finished higher on Nov 20 at $0.7852, a gain of 6.25% or $0.0462 per share, versus the S&P 500's 3.70% decline. Volume was 2.3x the average at 325.22K shares, a sign of unusually heavy trading. At this level, TLPH sits near the bottom of its 52-week range of $0.69 to $1.57: 50.0% below the high, set on Nov 24, 2025 and 13.8% above the low.

TLPH is down 31.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 41.4%. Talphera has posted a net loss over the last twelve months (EPS of -$0.21), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Talphera

Company profile

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat for IV infusion for disseminated intravascular coagulation, acute respiratory distress syndrome, acute pancreatitis, and an anti-viral treatment; Fedsyra, an ephedrine pre-filled syringe for injection; and a phenylephrine pre-filled syringe for injection.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Vincent J. Angotti
Headquarters
San Mateo, CA
Employees
12
IPO year
2011

Financial highlights

Full financials

In fiscal 2025, Talphera generated $28,000 in revenue, up 0.0% from fiscal 2024. Talphera reported a net loss of $14.3 million, compared with a loss of $13.0 million a year earlier. Operating margin was -48157.1%.

Talphera annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$28.00K$0$651.00K$0$2.82M
Growth—-100.00%—-100.00%-47.97%
Net income$-14.29M$-13.00M$-18.40M$47.76M$-35.10M
EPS (diluted)——$-1.29$5.72$-5.86

Analyst forecast

Forecast

Consensus (4 analysts)

none

Avg. price target

$3.13+298.62%

  • Strong buy 1
  • Buy 3
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $3.00High $3.50

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-0.11 vs $-0.06
Surprise
-83.33%

TLPH news

All TLPH news

Talphera peers

Health Care sector
TLPH peer companies
CompanyPrice% ChgMarket capCompare
ELTXElicio Therapeutics Inc.1.45-3.33%$41.05Mvs TLPH
MREOMereo BioPharma Group plc ADR0.26-5.45%$41.52Mvs TLPH
BMEABiomea Fusion Inc.0.5744-2.38%$41.75Mvs TLPH
OSTXOS Therapies Incorporated0.803-2.12%$42.00Mvs TLPH
DWTXDogwood Therapeutics Inc.1.04-2.36%$39.57Mvs TLPH
INCRIntercure Ltd.3.24-7.69%$42.03Mvs TLPH
CRBPCorbus Pharmaceuticals Holdings Inc.2.06-15.40%$42.45Mvs TLPH
SPROSpero Therapeutics Inc.0.742-10.20%$43.23Mvs TLPH

Indexes, lists and sector

Talphera stock FAQ

What is Talphera's stock price today?

TLPH last traded at $0.7852 as of Nov 20, 4:00 PM EST, up 6.25% on the day. Prices are delayed at least 15 minutes.

Does Talphera pay a dividend?

No. Talphera does not currently pay a regular cash dividend.

Who is Talphera's CEO?

Mr. Vincent J. Angotti is the chief executive officer of Talphera Inc., which has about 12 employees.

Has TLPH ever split its stock?

Yes. The most recent TLPH stock split was a 1-for-20 split on Oct 26, 2022.

What is the TLPH 52-week high?

The 52-week high for TLPH is $1.57 and the 52-week low is $0.69. The stock is currently 50.0% below its high.

Compare TLPH